Federal Court Dismisses Securities Class Action Against Agenus
AGEN has more than doubled off its 52-week low of $1.38.
Summary
Agenus Inc. has successfully obtained the dismissal of a putative securities class action lawsuit in Massachusetts federal court. The court granted the defendants' motion to dismiss the amended complaint in full and denied the plaintiff's request for leave to amend, effectively closing this stage of the litigation. This is a significant positive development for the small-cap biotechnology company, as it removes a substantial legal and financial overhang that could have resulted in considerable costs, management distraction, and reputational damage. While the company recently disclosed "going concern" doubts in its 10-K, this legal victory helps to mitigate one area of risk. Traders will now likely shift focus back to the progress of Agenus's clinical pipeline, particularly the recently advanced Phase 3 immunotherapy, and the company's overall financial health.
At the time of this announcement, AGEN was trading at $3.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $136.7M. The 52-week trading range was $1.38 to $7.34. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.